Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL910680 | 0.99 | S1PR1 (0.47) | S1PR1MAOAMAOBS1PR3S1PR5 | |
| SCHEMBL911404 | 0.89 | S1PR1 (0.57) | S1PR1S1PR3S1PR5ITGB3ITGA2B | |
| SCHEMBL11932190 | 0.88 | ALDH1A1 (0.52) | LTA4HALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL911345 | 0.83 | CA12 (0.47) | S1PR1S1PR3S1PR5ITGB3ITGA2B | |
| SCHEMBL910743 | 0.80 | MAOA (0.60) | MAOAMAOBITGB3ITGA2BALDH1A1 | |
| SCHEMBL917743 | 0.78 | PTPN1 (0.46) | ALDH1A1SCN3A | |
| SCHEMBL5003976 | 0.77 | TAAR1 (0.56) | TAAR1 | |
| SCHEMBL16220812 | 0.76 | DRD4 (0.59) | LTA4H | |
| SCHEMBL11932186 | 0.76 | KCNH2 (0.46) | ITGB3ITGA2BFFAR1LTA4H | |
| SCHEMBL11932192 | 0.76 | LMNA (0.58) | S1PR1S1PR3S1PR5FFAR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507497-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507497-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-1922073-B1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20120220606-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220606-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8211895-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211895-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110003832-A1 | NEW CAPPED Pyrazinoylguanidine SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003832-A1 | NEW CAPPED Pyrazinoylguanidine SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-7807834-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807834-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| WO-2007018640-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032509-A1 | New capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032509-A1 | New capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003832-A1 | NEW CAPPED Pyrazinoylguanidine SODIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, HCN4 | S1PR1 724/4885MAOA 1689/4885MAOB 926/4885 |
| US-20120220606-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, HCN4 | S1PR1 724/4885MAOA 1689/4885MAOB 926/4885 |
| US-20070032509-A1 | New capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | S1PR1 724/4885MAOA 1689/4885MAOB 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.